Latest Content
Sponsor content
Collaborative Research and Licensing Opportunity: Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules
NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. The applications for this hybridoma include its use in immuno-fluorescence (IF) microscopy; DNA/RNA immunoprecipitation (DRIP) and also in diagnostic kits for viral/bacterial infections, cancers, and a variety of other human diseases. NIH researchers have also incorporated the antibody into a micro-array platform, expanding its potential for use in diagnostic devices.
Sponsor content
Collaborative Research and Licensing Opportunity: Neutralizing Antibodies to Influenza HA and Their Use and Identification
Scientists at NIAID isolated families of antibodies capable of neutralizing diverse group 1 and group 2 influenza A viruses. The antibodies identified precisely targeted parts of the hemagglutinin (HA) protein, present on the surface of the influenza virus, that are least variable from season to season. A passive administration of members of these families of antibodies to individuals would represent an alternative to the current standard of care for severe influenza virus infection.
Sponsor content
Collaborative Research and Licensing Opportunity: PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have developed a novel CoV S protein vaccine antigen. This technology employs protein engineering to stabilize S in its prefusion conformation, preventing structural rearrangement, and exposing antigenically preferable surfaces. The technology has been applied to several CoV spikes, including those from human-relevant viruses, such as HKU1-CoV, SARS-CoV, and MERS-CoV. Particularly for MERS-COV, stabilized S proteins have been shown to elicit superior neutralizing antibody responses up to 10-fold higher in animal models and protect mice against lethal MERS-CoV infection.
Sponsor content
Collaborative Research and Licensing Opportunity: Novel Multivalent Nanoparticle Vaccines
Scientists at NIAID’s Vaccine Research Center are developing an alternative approach for design and production of seasonal influenza vaccines. The design includes recombinant fusion proteins that self-assemble into nanoparticles, referred to as mosaic nanoparticles, with influenza antigenic proteins displayed on the nanoparticle surface. Further engineering these recombinant fusion proteins, the scientists have developed nanoparticles that simultaneously display multiple strains of influenza viral protein antigens (the receptor-binding domain of hemagglutinin) on their surface.
Sponsor content
Collaborative Research and Licensing Opportunity: Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein hemagglutinin. By targeting this highly conserved region, which is nearly identical in various strains of influenza virus, these immunogens could train the immune system to defend against a wide variety of influenza strains including pandemic strains derived from animal reservoirs.
Sponsor content
Collaborative Research and Licensing Opportunity: Mononegavirales vectors expressing chimeric antigens
This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not exposed and that is not cross-protected with RSV, as a vector to express the RSV fusion (F) glycoprotein as an RSV vaccine candidate.
Using BioPharma Dealmakers
All about how to get the most from the BioPharma Dealmakers website, whether you are a sponsoring Company or a Member.
Editorial content
Follow us on Twitter
BioPharma Dealmakers has just joined Twitter. Follow us for details of our latest content and partnering news stories.
Editorial content
Looking to boost your company's profile and generate leads?
Key facts about our webcasts
Diagnostics dealmaking in the past year
Medtech dealmaking and financing trends in 2016
CNS
The latest from BioPharma Dealmakers on companies, research and deals in the CNS field.
Drug Development
The latest from BioPharma Dealmakers on companies, research and deals in the drug development field.
Academic/Non-profit organisation
The latest from BioPharma Dealmakers on establishments, research and deals from academic and non-profit organisations.
Opening up academic partnerships
Oncology
The latest from BioPharma Dealmakers on companies, research and deals in the oncology field.
Gastrointestinal
The latest from BioPharma Dealmakers on companies, research and deals in the gastrointestinal field.
Dealmaking for inflammatory disorders
Dermatology
The latest from BioPharma Dealmakers on companies, research and deals in the dermatology field.
